Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqBDLSF 27 EV-to-OCF is -3.07 as of Jul. 21, 2026. GuruFocus rates BDLSF with a GF Score™ of 27/100 and a GF Value™ of $0.29. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Inoviq ranks better than 65.26% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Inoviq's Enterprise Value is $10.08 Mil.
Inoviq's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.28 Mil. Therefore, Inoviq's EV-to-OCF for today is -3.07.
The historical rank and industry rank for Inoviq's EV-to-OCF or its related term are showing as below:
BDLSF'
s EV-to-OCF Range Over the Past 10 Years
Min: -27.02 Med: -7.15 Max: -3.21
Current: -3.21
During the past 13 years, the highest EV-to-OCF of Inoviq was -3.21. The lowest was -27.02. And the median was -7.15.
BDLSF's EV-to-OCF is ranked better than 65.26% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.18
vs BDLSF: -3.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-21), Inoviq's stock price is $0.12.
Inoviq's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.040. Therefore, Inoviq's PE Ratio (TTM) for today is At Loss.
Inoviq (OTCPK:BDLSF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inoviq's share price for today is $0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inoviq's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Inoviq EV-to-OCF Related Terms
Inoviq EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Inoviq's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inoviq's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Inoviq's EV-to-OCF falls into.
Inoviq's current Enterprise Value is $10.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inoviq's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (BDLSF) has a EV-to-OCF of -3.07 as of Jul. 21, 2026. According to the industry distribution chart, Inoviq ranks #74 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 34.7%.
Is Inoviq's EV-to-OCF too high?
Inoviq's current EV-to-OCF is -3.07. Based on the distribution chart, Inoviq ranks #74 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Inoviq has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Inoviq's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #74 out of 213 companies for EV-to-OCF. This puts Inoviq in the upper half of its industry. The industry median EV-to-OCF is 6.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.18, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current EV-to-OCF is -3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Inoviq (BDLSF) has a current EV-to-OCF of -3.07. The stock's GF Value™ is $0.29, compared to a current price of $0.12 — trading 58.6% below its estimated fair value. The current EV-to-OCF is -3.07. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Inoviq (BDLSF), the current EV-to-OCF is -3.07 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (BDLSF) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of $0.12 is trading 58.6% below its estimated GF Value™ of $0.29.
Key valuation signals for BDLSF:
EV-to-OCF: -3.07
GF Value™: $0.29 vs. price of $0.12 (58.6% below fair value)
No single metric tells the full story. See the BDLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for BDLSF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDLSF has been successfully added to your 
